Impact of COVID-19 on HIV and HCV Screening and Lessons Learned for 2022

Martin Hoenigl, MD, FECMM
Assistant Professor
Division of Infectious Diseases and Global Public Health
University of California San Diego

Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2022. All rights reserved.

Download Article PDF/Slides    

CME VIDEO

Top of page

How to Obtain CME Credit:

Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenters:

Top of page

Martin Hoenigl obtained his venia docendi in internal medicine in 2012 and is author to 185 pub med listed publications in the field of infectious diseases. His research currently focuses on acute HIV infection and HIV prevention, and also Clinical Mycology. Dr. Hoenigl received the Researcher of the Year award (2011) at the Medical University of Graz, and the Research Promotion award (2014) from the German Speaking Mycological Society.

Learning Objectives:

Top of page

At the completion of this educational session, learners will:
1. Know that HIV screening and linkage to care rates dropped significantly during the early phases of the pandemic, and that EMR driven automated emergency department HIV screening programs play a significant role in keeping up HIV screening during this public health emergency.
2. Understand the dynamics of HCV testing and treatment initiations during COVID-19, with HCV treatment rates failing to rebound.
3. Appreciate the important role of community-based programs for no-cost HIV and STI testing and treatment services and learn how these programs can be optimized to serve our client’s needs.

CME Information:

Top of page

This CME activity has approved for AMA PRA Category 1 Credit™ for June 15, 2022, as a live activity.  This activity will also be available as an enduring activity from June 16, 2022, through June 14, 2025.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:

Top of page

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:

Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:

Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.

- Dr. James F. Braun (Course Director) has no relevant financial relationships to disclose.

- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.

- Dr. Martin Hoenigl (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Research funding from Gilead, MSD, Scynexis, F2G, Euroimmune, Pfizer, Astellas, and Pulmocide. Dr. Hoenigl submitted their slides in advance for adequate peer review and will support their presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships have been mitigated.

Financial Support:

Top of page

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare